JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warner, T T
Right arrow Articles by Schapira, A H V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warner, T T
Right arrow Articles by Schapira, A H V
J Neurol Neurosurg Psychiatry 1998;65:378-379 ( September )

Short report

The role of the alpha -synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom T T Warner, A H V Schapira

University Department of Clinical Neurosciences, Royal Free Hospital School of Medicine, Rowland Hill Street, London, UK

Correspondence to: Dr T T Warner, University Department of Clinical Neurosciences, Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UK.

Received 21 November 1997 and in revised form 9 February 1998; Accepted 16 February

Parkinson's disease is a common neurodegenerative disorder of unknown aetiology. A pathogenic point mutation within the alpha -synuclein gene has recently been identified in one Italian-American kindred and three families of Greek origin with parkinsonism. DNA from 70 patients with Parkinson's disease was screened for this G209A mutation. No samples were positive for the mutation, suggesting that it is not relevant for most patients with sporadic idiopathic Parkinson's disease.

Keywords: Parkinson's disease; alpha -synuclein gene


© 1998 by Journal of Neurology, Neurosurgery, and Psychiatry



This article has been cited by other articles:


Home page
NeurologyHome page
A.H. V. Schapira
Neuroprotection in PD--A role for dopamine agonists?
Neurology, September 23, 2003; 61(90063): S34 - 42.
[Full Text]


Home page
BrainHome page
M. C. J. Dekker, V. Bonifati, and C. M. van Duijn
Parkinson's disease: piecing together a genetic jigsaw
Brain, August 1, 2003; 126(8): 1722 - 1733.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. H. V. Schapira
Neuroprotection and dopamine agonists
Neurology, February 1, 2002; 58(90001): S9 - 18.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
R. J. Perrin, W. S. Woods, D. F. Clayton, and J. M. George
Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins
J. Biol. Chem., November 2, 2001; 276(45): 41958 - 41962.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. J. Tabrizi, M. Orth, J. M. Wilkinson, J.-W. Taanman, T. T. Warner, J. M. Cooper, and A. H.V. Schapira
Expression of mutant {alpha}-synuclein causes increased susceptibility to dopamine toxicity
Hum. Mol. Genet., November 1, 2000; 9(18): 2683 - 2689.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 by the BMJ Publishing Group Ltd.